ERF:EURONEXT PARISEurofins Scientific SE Analysis

Eurofins Scientific (ERF) is trading at €61.48, well above its DCF‑derived fair value of €25.0, indicating a substantial premium. Technical signals are mixed: the 14‑day RSI sits at 30.7 (near oversold), while the MACD histogram is negative and the MACD line remains below its signal, suggesting bearish momentum. Price action hovers just above the identified support level of €60.32 and below the 20‑day SMA of €65.68, reinforcing a neutral to slightly bearish short‑term bias. The stock’s beta of 0.26 and 30‑day volatility of 23.3% point to relatively low market‑related risk, yet the company carries a high debt‑to‑equity ratio of 96.8%, which could amplify downside in stressed credit conditions. Fundamentals show modest revenue growth of 4.3% YoY, a gross margin of 22.5% and an operating margin of 13.3%, with free cash flow of €492 M supporting a 0.97% dividend yield and a comfortable payout ratio of 23.5%. The forward PE of 13.1 is below the industry average of 26.2, hinting at value appeal, but the elevated leverage and overvaluation relative to intrinsic estimates temper enthusiasm. Overall, the market sentiment is in “Greed” mode (Fear‑Greed Index 72.9), but material news is limited to routine regulatory filings and director share‑holding disclosures, offering no clear catalyst. Investors should weigh the attractive dividend and cash generation against the pricing premium and balance‑sheet risk before deciding on exposure.